MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Synageva BioPharma
Parents
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
*Architects: Infectious Disease _ HIV/AIDS & STDs
*Industry: Massachusetts
2013: The $100M Club: Where the Major League Life Sciences Companies Are (2013)
Companies: Acquiring (M&A)
Children
Clinical-stage biopharma focused on rare diseases and orphan therapeutics for the treatment of lysosomal storage disease and metabolic disorders
Closed a $25M Series C financing (2011)
Lexington, Massachusetts
Participants have included New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson and Four Partners.
Synageva BioPharma Announces Additional $25 Million Funding to Support Rare Disease Product Development
Synageva to go public with Trimeris M&A (2011)
Trimeris Inc. (Nasdaq: TRMS)